Analysis of Anti-Glycan IgG and IgM Antibodies in Colorectal Cancer

We propose an approach that allows simultaneous determination of the levels of M and G isotypes of antibodies to the panel of glycans using microarrays. The level of IgG antibodies to 3’-O-su-Le a glycan detects patients with colorectal cancer with a sensitivity of 69.77% and specificity of 62.75%....

Full description

Saved in:
Bibliographic Details
Published in:Bulletin of experimental biology and medicine 2019-02, Vol.166 (4), p.489-493
Main Authors: Tikhonov, A. A., Savvateeva, E. N., Chernichenko, M. A., Maslennikov, V. V., Sidorov, D. V., Rubina, A. Yu, Kushlinskii, N. E.
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Analysis
Antibodies
Antibodies - immunology
Antibodies, Anti-Idiotypic - immunology
Biomedical and Life Sciences
Biomedicine
Cancer patients
Cell Biology
Colorectal cancer
Colorectal carcinoma
Colorectal Neoplasms - immunology
Diagnosis
Female
Humans
Immunoglobulin G
Immunoglobulin G - immunology
Immunoglobulin M
Immunoglobulin M - immunology
Immunoglobulins
Internal Medicine
Isotypes
Laboratory Medicine
Male
Metastases
Middle Aged
Oncology
Pathology
Polysaccharides
Polysaccharides - immunology
Povidone
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We propose an approach that allows simultaneous determination of the levels of M and G isotypes of antibodies to the panel of glycans using microarrays. The level of IgG antibodies to 3’-O-su-Le a glycan detects patients with colorectal cancer with a sensitivity of 69.77% and specificity of 62.75%. The percentage of correctly classified colorectal cancer patients with the use of a combination of two markers IgM antibodies to glycans 3’-sialyl-TF and 3’-O-su-Le a is as high as 74.23%. The levels of IgM antibodies to 3’-O-su-Le a glycan differ significantly in patients with and without regional metastases. The levels of some of antiglycan IgM or IgG antibodies differed significantly in patients with tumors of different location and differentiation.
ISSN:0007-4888
1573-8221
DOI:10.1007/s10517-019-04379-2